Direct Meds Review

Direct Meds is a cash-pay technology platform connecting patients with independent medical providers and pharmacies. Its current footer publishes a Houston mailing address, phone number, and help email. The terms repeatedly call the operator directmeds.com but do not name a corporation or limited liability company, so patients should identify the legal party in the checkout agreement.

For injectable weight management, the current transaction pages show compounded semaglutide at $297 and compounded tirzepatide at $399 per month. Both visible options are labeled 90 Day Supply, show free shipping, and say there is no separate membership fee.

Semaglutide support documentation reconstructs the starter price as $891 for three bottles, split into three $297 payments. The embedded transaction option independently records a 90-day supply, three supply months, monthly billing, and a three-period commitment.

The tirzepatide transaction option records the same three-month structure at $399 per billing period, which implies $1,197 across the starter period. Its dedicated support price article still says $497 and is mislabeled as semaglutide pricing. Another current campaign page says $447. The transaction option is the most direct current purchase source, but the discrepancy should be resolved before payment.

The issued affiliate route currently lands on a Direct Meds page advertising a summer discount of $150 instantly and a $147 starting charge. The same page also labels product tiles as up to $200 off. It does not publish one complete set of product eligibility, expiration, stacking, refund, or later-charge terms, so the draft describes only the current headline and requires checkout confirmation.

Direct Meds says the GLP-1 monthly price includes provider review, medication when prescribed, injection supplies, shipping, and ongoing support. A current semaglutide support article adds that three starter bottles ship together. No separate access or membership fee is advertised for these options.

The care path begins with a short health qualifier, treatment selection, payment, and a more complete medical intake in the patient portal. A licensed provider reviews the chart, may request more information, and decides whether a prescription is clinically appropriate. Current pages estimate review within one business day and sometimes within five hours, but that is not a guaranteed service level.

Provider pages say patients receive a full refund if the clinician does not approve the prescription. The formal terms also include medication denied by a Direct Meds doctor among the narrow return or refund exceptions. Readers should still confirm whether any consultation, platform, or processing amount can be retained.

Direct Meds names Justin Hohl, MD, as chief medical officer. The federal NPI record for Justin B. Hohl is active and lists orthopaedic surgery in Utah. An NPI confirms an administrative identity, not a current license in every state, weight-management specialization, or assignment to an individual patient.

Current product pages map many states to CraftedRx in Warrenton, Missouri, and six states to Chemistry Rx in Folcroft, Pennsylvania. Both pharmacy trade names and addresses can be matched to pharmacy sources, which is more useful than an entirely anonymous network. Patients should still confirm which entity will fill their specific prescription and that its license covers their state.

Pharmacy classification is inconsistent. The dedicated product pages call the partners 503B pharmacies, while the current affiliate landing page and support center describe U.S.-based 503A pharmacies. Neither CraftedRx nor Chemistry Rx appears under those trade names on FDA's current registered outsourcing-facility list. That does not determine every affiliated entity or prescription pathway, but it means the 503B label should not be accepted without clarification.

Compounded drugs are not FDA approved. FDA does not verify their safety, effectiveness, or quality before marketing and says compounded GLP-1 products should be used only when a patient's medical needs cannot be met by an approved drug. A patient should ask the prescriber to document the individualized reason for the compounded option.

The tirzepatide page needs particular caution. It labels the product compounded, then also says FDA approved for long term weight loss and describes a prefilled pen even though the program elsewhere describes vials and syringes. Its intake section mistakenly asks whether compounded semaglutide is appropriate. These are material content errors, not evidence about the product actually dispensed.

Direct Meds also markets sublingual semaglutide and tirzepatide. The support center lists sublingual semaglutide at $249 monthly, but route-specific formulation, concentration, ingredient form, quantity, absorption evidence, and current tirzepatide price are not complete enough for separate comparison cards. They remain route variants under their canonical active ingredients.

The wider storefront includes hormone, longevity, hair, skin, sexual-health, and other treatments. Its women's hormone program is a clinician-selected bundle that may include estradiol, progesterone, vaginal estradiol, and DHEA for one shared price. A bundle price cannot be assigned to each ingredient, so the review does not create extra therapy cards from those branded offerings.

Current weight-management pages say service is available in every U.S. state except Mississippi and Louisiana. That is a provider statement, not a guarantee that every formulation, pharmacy, and clinician is available in each remaining state. Eligibility should be confirmed for the selected treatment and shipping address.

Shipping guidance says U.S. pharmacies generally process orders within two to three business days after receiving the prescription, ship Monday through Thursday, and use UPS or FedEx Next-Day Air for temperature-controlled products. Product and campaign pages separately promise shipping within one or two days and sometimes same-day processing. The support-center range is the more cautious planning estimate.

Direct Meds says shipments include tracking and insurance for lost packages except when the patient supplied an incorrect or incomplete address. Its delay guidance tells patients not to use medication that arrived warm or otherwise concerning until the pharmacy or prescriber advises them. Shipment issues should be reported within forty-eight hours.

Cancellation language requires close reading. Product pages say cancel anytime and no contracts. Embedded options record a three-period commitment, the terms require cancellation at least forty-eight hours before processing, and U.S. support documentation says patients cannot currently change subscriptions directly in the portal. Ask Patient Services to confirm the exact remaining obligation in writing.

Prescription orders generally cannot be canceled after twenty-four hours under the terms, and shipped medication is ordinarily nonrefundable. The formal policy lists narrow exceptions for wrong, damaged, unsafe, unshipped, or clinician-denied products and describes a $35 disposal fee for returned medication. Support documentation says refund requests are reviewed case by case.

Patient Services publishes phone support daily from 9 AM to 9 PM ET and accepts online messages at any time, with staff responding during those daily hours. U.S. live chat is listed Monday through Friday from 9 AM to 9 PM ET. Clinical questions are routed through the patient portal, but no guaranteed clinical response time is published.

No universal GLP-1 laboratory schedule appears on the current public weight-management pages. The broader hormone program says at-home testing may be included when clinically appropriate, but that cannot be transferred to the injectable GLP-1 program. Ask what baseline or follow-up testing the assigned provider requires and whether it is included.

The most defensible checkout record is the exact product option, payment schedule, recurring charge, cancellation cutoff, and refund language shown immediately before authorization. Marketing headlines, support articles, and embedded transaction data currently disagree often enough that screenshots or a saved confirmation are worthwhile.

Before starting, confirm the clinician and medical practice, dispensing pharmacy and section 503A or 503B pathway, active ingredient form, additives such as vitamin B12, concentration, prescribed milligrams, syringe units, vial count, beyond-use date, storage limits, laboratory plan, starter total, renewal price, and process for adverse effects or a warm shipment.